RESEARCH TRIANGLE PARK, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced that LKH-Universitätsklinikum Graz in Austria has entered into an agreement to lease and utilize a Senhance® Surgical System.
LKH-Universitätsklinikum Graz is a renowned healthcare institution known for its expertise in minimally invasive pediatric and adolescent surgery. This hospital will be the 7th pediatric-focused site to utilize the state-of-the-art Senhance Surgical System using 3mm and 5mm instruments for a variety of minimally invasive procedures.
“We are thrilled to collaborate with LKH-Universitätsklinikum Graz for the initiation of our Senhance Surgical System clinical program,” said Anthony Fernando, Asensus Surgical President and CEO. “This collaboration demonstrates our commitment to expanding the adoption of our innovative surgical platform to benefit patients and healthcare providers around the world.”
"We are excited to partner with Asensus Surgical and incorporate the Senhance Surgical System into our clinical practice," said Professor Holger Till, Head of the Department of Pediatric and Adolescent Surgery at LKH-Universitätsklinikum Graz. "The Senhance System is the first platform to offer 3mm instruments. These small instruments have the potential to enhance surgical outcomes for our young patients, and we look forward to advancing the field of pediatric and adolescent surgery with this cutting-edge platform.”
The Senhance Surgical System is being recognized as an advanced robotic option for pediatric procedures
About LKH-Universitätsklinikum Graz
LKH-Universitätsklinikum Graz is a leading healthcare institution located in Graz, Austria, with a reputation for excellence in medical care, research, and education. The hospital is affiliated with the Medical University of Graz and serves as a prominent center for healthcare delivery, innovation, and academic excellence in the region. LKH-Universitätsklinikum Graz has a comprehensive Department of Pediatric and Adolescent Surgery specializing in providing surgical care for infants, children, and adolescents with a wide range of conditions. The highly skilled and experienced team of surgeons utilizes advanced surgical techniques and state-of-the-art technology to deliver exceptional care and optimize patient outcomes. As a leading institution in Austria, LKH-Universitätsklinikum Graz is committed to advancing the field of pediatric and adolescent surgery through continuous research, innovation, and collaboration with global partners. The hospital is dedicated to providing the highest standard of care to its patients, while also serving as a center for education and training for the next generation of healthcare professionals. With a strong focus on patient-centric care, cutting-edge technology, and interdisciplinary collaboration, LKH-Universitätsklinikum Graz strives to improve the health and well-being of its patients, contribute to scientific advancement, and shape the future of healthcare in Austria and beyond.
About Asensus Surgical, Inc.
Asensus Surgical is revolutionizing surgery with the first intra-operative Augmented Intelligence technology approved for use in operating rooms around the world. Recognized as an award-winning leader in digital technology, Asensus is committed to making surgery more accessible and predictable while delivering consistently superior outcomes. The Company’s novel approach to digitizing laparoscopy has led to system placements globally. Led by engineers, medical professionals, and industry luminaries, Asensus is powered by human ingenuity and driven by collaboration. To learn more about Asensus, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc/
X: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
TikTok:https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance Surgical System and LKH-Universitätsklinikum Graz initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the collaboration with LKH-Universitätsklinikum Graz demonstrates our commitment to expanding the adoption of the Senhance System platform to benefit patients and healthcare providers around the world and whether the Senhance System will help LKH-Universitätsklinikum Graz advance the field of pediatric and adolescent surgery. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 22, 2024 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
443-213-0499
MEDIA CONTACT:
Dan Ventresca
Matter Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-874-5488
Last Trade: | US$0.35 |
Daily Volume: | 0 |
Market Cap: | US$94.920M |
August 13, 2024 July 24, 2024 July 23, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB